Texas Instruments (NASDAQ: TXN | TXN Price Prediction) stock has climbed from roughly $162.74 per share in October 2025 to $236.31 at its Q1 FY26 filing on April 22, 2026, a roughly six-month run that pushed the analog giant to a multi-year high and a market cap near $256.96 billion. For investors who watched it happen and did nothing, the question stinging right now is the obvious one: is there anything left on the table, or did the easy money already leave the station? Let’s work through it honestly.
Valuation: Expensive, but Earnings Are Accelerating Into It
Texas Instruments trades at roughly 43x trailing earnings on FY2025 EPS of $5.45. That is a premium multiple for a cyclical analog chipmaker, and there is no way to dress it up otherwise. The offset is that earnings are rising faster than the price. Q1 FY26 delivered revenue of $4.83 billion, up 18.6% year over year, beating the $4.53 billion consensus, with diluted EPS of $1.68, beating the $1.36 consensus estimate. Q2 guidance calls for revenue of $5.00 billion to $5.40 billion and EPS of $1.77 to $2.05. Running the forward numbers suggests the multiple compresses meaningfully for 2026. Investors are paying up, but they are paying up for visibly accelerating profitability.
Forward Catalyst: The Analog Cycle Turned
The cycle-recovery thesis shows up clearly in the segment data. Analog revenue hit $3.92 billion, up 22% year over year, with operating profit up 36%. Embedded Processing grew 12% with operating profit up 205%. CEO Haviv Ilan told investors, “Revenue increased 9% sequentially and 19% from the same quarter a year ago with growth led by industrial and data center.” Capex is moderating as the 300mm wafer build-out pays off: Q1 capex fell 40% year over year to $676 million while free cash flow jumped to $1.40 billion, up 610% year over year. The company also pocketed $555 million in CHIPS Act incentive proceeds in the quarter. Dividend growth is funded, buybacks continue at a $982 million trailing-12-month pace, and $6.0 billion was returned to owners over the past year. The story that lifted the stock from the $160s is still intact and, by the numbers, strengthening.
Downside Risk: What Happens If the Thesis Is Wrong
The honest risks cannot be overlooked. A multiple in the 40s leaves no margin if the industrial or automotive cycle rolls over again, and both end markets are classically cyclical. Tariff and trade-policy noise remains a live variable for a company with meaningful China exposure. Execution can wobble, as it did when Q4 FY25 produced a 3.05% EPS miss. And an all-time-high entry carries a simple mathematical reality: if the forward earnings ramp slips a quarter, the multiple compresses before it catches up. A pullback to the low $200s on a single soft guide is entirely plausible.
The Verdict
The stock is no longer cheap, though the thesis still has runway. With free cash flow inflecting, capex rolling over, a reliable dividend, and an analog cycle that just confirmed its turn, the setup still favors patient buyers, particularly retirement-focused investors who want income and a long runway. For existing shareholders, the fundamentals support staying engaged. And for investors considering new exposure, waiting for weakness toward the low $200s offers a better risk/reward than chasing an all-time-high print.
Top Gaining Stocks
Top Losing Stocks